Analysis of overall metastatic cancer events revealed that efpeglenatide, one of the GLP-1 receptor agonists, was associated with significantly fewer events of overall metastatic cancers than the controls [odds ratio (OR) = 0.26, 95% confidence intervals (95%CIs) = 0.09 to 0.70, incidence in efpeglenatide group and control group = 0.145% and 0.676%, respectively, number needed to treat (NNT) = 188.4]. The gene discussed is GLP1R; the disease is metastatic malignant neoplasm.